These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 19584272)

  • 21. Germline mutations in cancer susceptibility genes in high grade serous ovarian cancer in Serbia.
    Krivokuca A; Boljevic I; Jovandic S; Magic Z; Mandic A; Tomasevic Z; Brankovic-Magic M
    J Hum Genet; 2019 Apr; 64(4):281-290. PubMed ID: 30651582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic predisposition to breast cancer: past, present, and future.
    Turnbull C; Rahman N
    Annu Rev Genomics Hum Genet; 2008; 9():321-45. PubMed ID: 18544032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cell cycle-dependent complex formation of BRCA1.CtIP.MRN is important for DNA double-strand break repair.
    Chen L; Nievera CJ; Lee AY; Wu X
    J Biol Chem; 2008 Mar; 283(12):7713-20. PubMed ID: 18171670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer.
    Kessous R; Octeau D; Klein K; Tonin PN; Greenwood CMT; Pelmus M; Laskov I; Kogan L; Salvador S; Lau S; Yasmeen A; Gotlieb WH
    Gynecol Oncol; 2018 Mar; 148(3):553-558. PubMed ID: 29395310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Translational advances regarding hereditary breast cancer syndromes.
    Gage M; Wattendorf D; Henry LR
    J Surg Oncol; 2012 Apr; 105(5):444-51. PubMed ID: 22441895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
    Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
    JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing.
    Zhao W; Steinfeld JB; Liang F; Chen X; Maranon DG; Jian Ma C; Kwon Y; Rao T; Wang W; Sheng C; Song X; Deng Y; Jimenez-Sainz J; Lu L; Jensen RB; Xiong Y; Kupfer GM; Wiese C; Greene EC; Sung P
    Nature; 2017 Oct; 550(7676):360-365. PubMed ID: 28976962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of Mre11 in chromosomal nonhomologous end joining in mammalian cells.
    Rass E; Grabarz A; Plo I; Gautier J; Bertrand P; Lopez BS
    Nat Struct Mol Biol; 2009 Aug; 16(8):819-24. PubMed ID: 19633668
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
    McLaughlin JR; Risch HA; Lubinski J; Moller P; Ghadirian P; Lynch H; Karlan B; Fishman D; Rosen B; Neuhausen SL; Offit K; Kauff N; Domchek S; Tung N; Friedman E; Foulkes W; Sun P; Narod SA;
    Lancet Oncol; 2007 Jan; 8(1):26-34. PubMed ID: 17196508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families.
    Guénard F; Labrie Y; Ouellette G; Joly Beauparlant C; Simard J; ; Durocher F
    J Hum Genet; 2008; 53(7):579. PubMed ID: 18414782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.
    Couch FJ; Gaudet MM; Antoniou AC; Ramus SJ; Kuchenbaecker KB; Soucy P; Beesley J; Chen X; Wang X; Kirchhoff T; McGuffog L; Barrowdale D; Lee A; Healey S; Sinilnikova OM; Andrulis IL; ; Ozcelik H; Mulligan AM; Thomassen M; Gerdes AM; Jensen UB; Skytte AB; Kruse TA; Caligo MA; von Wachenfeldt A; Barbany-Bustinza G; Loman N; Soller M; Ehrencrona H; Karlsson P; ; Nathanson KL; Rebbeck TR; Domchek SM; Jakubowska A; Lubinski J; Jaworska K; Durda K; Zlowocka E; Huzarski T; Byrski T; Gronwald J; Cybulski C; Górski B; Osorio A; Durán M; Tejada MI; Benitez J; Hamann U; Hogervorst FB; ; van Os TA; van Leeuwen FE; Meijers-Heijboer HE; Wijnen J; Blok MJ; Kets M; Hooning MJ; Oldenburg RA; Ausems MG; Peock S; Frost D; Ellis SD; Platte R; Fineberg E; Evans DG; Jacobs C; Eeles RA; Adlard J; Davidson R; Eccles DM; Cole T; Cook J; Paterson J; Brewer C; Douglas F; Hodgson SV; Morrison PJ; Walker L; Porteous ME; Kennedy MJ; Side LE; ; Bove B; Godwin AK; Stoppa-Lyonnet D; ; Fassy-Colcombet M; Castera L; Cornelis F; Mazoyer S; Léoné M; Boutry-Kryza N; Bressac-de Paillerets B; Caron O; Pujol P; Coupier I; Delnatte C; Akloul L; Lynch HT; Snyder CL; Buys SS; Daly MB; Terry M; Chung WK; John EM; Miron A; Southey MC; Hopper JL; Goldgar DE; Singer CF; Rappaport C; Tea MK; Fink-Retter A; Hansen TV; Nielsen FC; Arason A; Vijai J; Shah S; Sarrel K; Robson ME; Piedmonte M; Phillips K; Basil J; Rubinstein WS; Boggess J; Wakeley K; Ewart-Toland A; Montagna M; Agata S; Imyanitov EN; Isaacs C; Janavicius R; Lazaro C; Blanco I; Feliubadalo L; Brunet J; Gayther SA; Pharoah PP; Odunsi KO; Karlan BY; Walsh CS; Olah E; Teo SH; Ganz PA; Beattie MS; van Rensburg EJ; Dorfling CM; Diez O; Kwong A; Schmutzler RK; Wappenschmidt B; Engel C; Meindl A; Ditsch N; Arnold N; Heidemann S; Niederacher D; Preisler-Adams S; Gadzicki D; Varon-Mateeva R; Deissler H; Gehrig A; Sutter C; Kast K; Fiebig B; Heinritz W; Caldes T; de la Hoya M; Muranen TA; Nevanlinna H; Tischkowitz MD; Spurdle AB; Neuhausen SL; Ding YC; Lindor NM; Fredericksen Z; Pankratz VS; Peterlongo P; Manoukian S; Peissel B; Zaffaroni D; Barile M; Bernard L; Viel A; Giannini G; Varesco L; Radice P; Greene MH; Mai PL; Easton DF; Chenevix-Trench G; ; Offit K; Simard J;
    Cancer Epidemiol Biomarkers Prev; 2012 Apr; 21(4):645-57. PubMed ID: 22351618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proteasome function is required for DNA damage response and fanconi anemia pathway activation.
    Jacquemont C; Taniguchi T
    Cancer Res; 2007 Aug; 67(15):7395-405. PubMed ID: 17671210
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cleavage of the BRCT tandem domains of nibrin by the 657del5 mutation affects the DNA damage response less than the Arg215Trp mutation.
    Mendez G; Cilli D; Berardinelli F; Viganotti M; Ascenzi P; Tanzarella C; Antoccia A; di Masi A
    IUBMB Life; 2012 Oct; 64(10):853-61. PubMed ID: 22941933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HP1 regulates the localization of FANCJ at sites of DNA double-strand breaks.
    Wu W; Togashi Y; Johmura Y; Miyoshi Y; Nobuoka S; Nakanishi M; Ohta T
    Cancer Sci; 2016 Oct; 107(10):1406-1415. PubMed ID: 27399284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The BARD1 Cys557Ser variant and breast cancer risk in Iceland.
    Stacey SN; Sulem P; Johannsson OT; Helgason A; Gudmundsson J; Kostic JP; Kristjansson K; Jonsdottir T; Sigurdsson H; Hrafnkelsson J; Johannsson J; Sveinsson T; Myrdal G; Grimsson HN; Bergthorsson JT; Amundadottir LT; Gulcher JR; Thorsteinsdottir U; Kong A; Stefansson K
    PLoS Med; 2006 Jul; 3(7):e217. PubMed ID: 16768547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetically determined subdivision of human populations with respect to the risk of breast cancer in women.
    Tarasov VA; Aslanyan MM; Tsyrendorzhiyeva ES; Litvinov SS; Gar'kavtseva RF; Altukhov YP
    Dokl Biol Sci; 2006; 406():66-9. PubMed ID: 16572816
    [No Abstract]   [Full Text] [Related]  

  • 37. Impairment of double-strand breaks repair and aberrant splicing of ATM and MRE11 in leukemia-lymphoma cell lines with microsatellite instability.
    Ham MF; Takakuwa T; Luo WJ; Liu A; Horii A; Aozasa K
    Cancer Sci; 2006 Mar; 97(3):226-34. PubMed ID: 16542220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Are the so-called low penetrance breast cancer genes, ATM, BRIP1, PALB2 and CHEK2, high risk for women with strong family histories?
    Byrnes GB; Southey MC; Hopper JL
    Breast Cancer Res; 2008; 10(3):208. PubMed ID: 18557994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanism of BRCA1-BARD1 function in DNA end resection and DNA protection.
    Ceppi I; Dello Stritto MR; Mütze M; Braunshier S; Mengoli V; Reginato G; Võ HMP; Jimeno S; Acharya A; Roy M; Sanchez A; Halder S; Howard SM; Guérois R; Huertas P; Noordermeer SM; Seidel R; Cejka P
    Nature; 2024 Oct; 634(8033):492-500. PubMed ID: 39261728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors.
    Honrado E; Osorio A; Palacios J; Milne RL; Sánchez L; Díez O; Cazorla A; Syrjakoski K; Huntsman D; Heikkilä P; Lerma E; Kallioniemi A; Rivas C; Foulkes WD; Nevanlinna H; Benítez J
    J Clin Oncol; 2005 Oct; 23(30):7503-11. PubMed ID: 16234517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.